Suzhou Industrial Park Heshun Electric
300141
Guangdong Xiongsu Technology Group
300599
Sichuan Chuanhuan Technology
300547
Shanghai Wisdom Information Technology
301315
KANGNONG SEED
837403
CN Stock MarketDetailed Quotes
301257 SMO Clinplus
- 28.46
- +0.12+0.42%
Market Closed Dec 27 15:00 CST
2.26BMarket Cap21.33P/E (TTM)
28.74High28.22Low12.54KlotVolume28.30Open28.34Pre Close35.75MTurnover2.64%Turnover Ratio16.79P/E (Static)79.51MShares49.5352wk High1.98P/B1.35BFloat Cap22.9252wk Low34.01Limit Up47.51MShs Float65.44Historical High22.67Limit Down1.84%Amplitude22.92Historical Low0.33Dividend TTM28.52Avg Price6.34KlotAsk1.16%Div YieldTTM100Lot Size6.10KlotBid
SMO Clinplus News
Puruis (301257.SZ): Currently not participating in any clinical research projects related to Brain-computer Interface.
On December 19, Gelonghui reported that Pruess (301257.SZ) stated on the investor interaction platform that the company is currently not involved in any clinical research projects related to Brain-computer Interface, and the company will continue to pay attention to Industry trends and customer needs.
Express News | Summary of shareholding reductions of listed companies on December 2.
Express News | Puruis: Shareholders plan to reduce their shareholding by no more than 1.9% of the company's shares.
Express News | 20 companies were surveyed by funds, zhejiang viewshine intelligent meter being the most attention-grabbing among them.
Pures (301257) 2024 third quarter report review: short-term performance under pressure, continuous expansion of personnel.
Event: The company released the third quarter report of 2024, achieving revenue of 0.594 billion yuan in the first three quarters of 2024 (+9.17% year-on-year), achieving a net income attributable to the parent company of 0.072 billion yuan (-28.39% year-on-year).
Pures (301257): Revenue below expectations, profits somewhat under pressure.
Event: On October 29, the company released the third quarter report of 2024, achieving revenue of 0.594 billion yuan in the first three quarters of 2024, a year-on-year increase of 9.17%, with a net income attributable to the parent company of 0.072 billion yuan, a year-on-year decrease of 28.3%.
Prius: Third quarter report 2024
Puresis (301257.SZ) released its performance for the first three quarters, with a net income of 72.2643 million yuan, a decrease of 28.39%.
Puresis (301257.SZ) released the third quarter report of 2024. The company's revenue for the first three quarters was 5....
Pruess (301257.SZ) net income in the first three quarters was 72.2643 million yuan, a decrease of 28.39% year-on-year.
Grace Times reported on October 29th that Prose (301257.SZ) released the third quarter report of 2024, with the company achieving revenue of 0.594 billion yuan in the first three quarters, a year-on-year increase of 9.17%; net income of 72.2643 million yuan, a year-on-year decrease of 28.39%. Among them, the third quarter achieved revenue of 0.199 billion yuan, a year-on-year increase of 2.03%; net income of 17.3413 million yuan, a year-on-year decrease of 55.50%.
Puresci (301257.SZ): Shareholders Zhaotai and Huiqiao Hongjia plan to collectively reduce their shareholding by no more than 2.7%.
On October 15th, Grong Hui announced that the shareholder Guan Yu plans to reduce the company's shares in a centralized bidding and/or block trade manner within 3 months after 15 trading days from the date of this announcement, not exceeding 1,590,100 shares (1.9999% of the company's total share capital). Huiqiao Hongjia plans to reduce the company's shares in a block trading and/or centralized bidding manner within 3 months after 3 trading days from the date of this announcement, not exceeding 557,300 shares (0.7009% of the company's total share capital).
Express News | Puris: Shareholders plan to reduce their shareholding.
Puresun (301257.SZ) plans to distribute a dividend of 1.5 yuan per 10 shares, with the ex-dividend date on October 10th.
Pures (301257.SZ) announced that the company's 2024 interim equity distribution plan: 0.5 yuan (including tax) will be distributed to all shareholders for every 10 shares held.
Pricer (301257.SZ): The new signed contract amount in the second quarter increased by 112.14% compared to the first quarter excluding taxes.
Gelonghui, September 25th | Puris (301257.SZ) recently conducted surveys with specific entities regarding the 'new order situation of the company in the first half of 2024?' The company stated that in the first half of 2024, the company's new signed untaxed contract amount was 0.429 billion yuan, a year-on-year decrease of 31.89%. This was mainly due to the structural and cyclical impact on the biomedical industry leading to effects on the supply and demand sides, intensified competition within the industry, a decrease in order prices, and the company selectively sacrificing orders that did not meet certain profit indicators to achieve long-term sustainable profit growth. Orders in the second quarter of 2024.
Puresis (301257): Industry adjustments bring volatility, Q2 improves compared to the previous quarter.
The company released its 2024 interim report. In the first half of 2024, the company achieved revenue of 0.394 billion yuan, a year-on-year increase of 13.16%; and achieved a net income of 54.923 million yuan attributable to shareholders, a year-on-year decrease of 11.
Puresis (301257): Government subsidies reduce the impact on profit performance, and demand gradually picks up.
Event: Puris announces its 2024 interim report. The company achieved revenue of 0.394 billion yuan in H1 2024 (+13.16% year-on-year), net income attributable to shareholders of 0.055 billion yuan (-11.33% year-on-year), after deducting
Prius: 2024 Semi-Annual Report
Prius: 2024 Semi-Annual Report Summary
Puresis (301257.SZ) announced its performance for the first half of the year, with a net income of 54.923 million yuan, a decrease of 11.33% year-on-year.
Pures (301257.SZ) released the semi-annual report for 2024, with the company achieving revenue of 3....
PRASYS (301257): Revenue growth meets expectations, Q2 new order signing improves QoQ.
Event: On August 29, the company released its semi-annual report for 2024. In the first half of 2024, the company achieved revenue of 0.394 billion yuan, an increase of 13.16% year-on-year. The net income attributable to the parent company was 0.055 billion yuan, a decrease of 11.33% year-on-year.
Express News | Pfizer: The company is currently not involved in any clinical research projects related to smallpox disease.
